Comparing Safety and Efficacy of Novel AML Agents Against Established Regimens

EP: 1.Overview of Pathophysiology of and Progression of AML

EP: 2.Risk Classification Systems in AML

EP: 3.Key Patient Factors to Consider in AML Treatment Decisions

EP: 4.Provider Perspectives on Biggest Unmet Needs in AML Care

EP: 5.Social Determinants to AML Treatment Approach

EP: 6.Latest NCCN Guidelines on the Standard of Care for Patients With AML

EP: 7.Patient Eligibility for Transplant, Induction, and Consolidation in AML Treatment

EP: 8.Venetoclax and the Impact on Management of Older Patients With AML

EP: 9.Combination Therapies in AML Treatment Approach

EP: 10.Tracking the Shifting Treatment Landscape of AML

EP: 11.Expert Perspectives on IDH Inhibitors in AML Treatment

EP: 12.Managing Toxicities in Patients With AML

Now Viewing

EP: 13.Comparing Safety and Efficacy of Novel AML Agents Against Established Regimens

EP: 14.Newly Diagnosed Patients With AML: Discussing Implications of Recent Trial Results

Patients with acute myeloid leukemia (AML) now have access to multiple novel therapeutic agents representing different mechanism classes, with menin inhibitors emerging as particularly promising treatments for specific genetic subtypes. The first-in-class menin inhibitor revumenib received approval for relapsed/refractory AML, with additional approvals expected for other menin inhibitors targeting NPM1-mutated disease, which affects approximately 35% of patients. Unlike the disappointing results seen with CD47 inhibitor programs that failed multiple phase 3 trials, menin inhibitors have demonstrated consistent clinical benefit across different compounds in the class, suggesting the pathway represents a genuinely important therapeutic target.

The success of menin inhibitors contrasts sharply with the challenges faced by CD47-targeted therapies, which showed promising preclinical results but failed to translate into meaningful clinical benefits due to significant toxicity issues, particularly severe anemia. Patients considered for CD47 inhibitor trials faced substantial adverse effect burdens without corresponding survival benefits, leading to the discontinuation of multiple development programs. This experience highlights the importance of rigorous clinical testing and the reality that promising laboratory results don’t always predict clinical success for patients.

Looking toward the future, patients can expect menin inhibitors to move into frontline treatment combinations, similar to the successful development path of FLT3 and IDH inhibitors. The potential for menin inhibitors in combination with hypomethylating agents and other targeted therapies could benefit substantial numbers of patients, given that NPM1 mutations represent one of the most common genetic alterations in AML. Early clinical trial data suggests that frontline combination approaches may provide the greatest benefit, offering patients with these specific mutations access to highly effective, targeted treatment regimens that could significantly improve long-term outcomes.